文献速递妇科

度伐利尤单抗联合奥拉帕利治疗转移性或复发性子宫内膜癌的疗效与安全性(II期DOMEC试验)

Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
PubMed 文献 · Gynecol Oncol · 2022-03-11

DOMEC是一项多中心II期试验,评估度伐利尤单抗联合奥拉帕利治疗转移性或复发性子宫内膜癌。共入组55例,50例可评估,6个月无进展生存率为34%,客观缓解率16%,中位无进展生存期3.4个月,中位总生存期8.0个月。联合方案耐受性良好,但未达到预设的6个月无进展生存率≥50%的疗效标准。

要点

  • 6个月无进展生存率为34%,未达到预设的≥50%疗效标准。
  • 客观缓解率16%,含1例完全缓解和7例部分缓解。
  • 3级治疗相关不良事件发生率为16%,以贫血为主,无4级或5级事件。

核心结论

  • 度伐利尤单抗联合奥拉帕利耐受性良好,但在该异质性晚期子宫内膜癌人群中未达到预设的6个月无进展生存率≥50%的疗效标准。

研究设计与样本

  • 研究者发起的多中心II期DOMEC试验(NCT03951415),入组转移性或复发性子宫内膜癌患者,接受度伐利尤单抗1500 mg静脉注射每4周一次联合奥拉帕利300 mg每日两次口服,直至疾病进展、不可耐受毒性或患者退出;治疗至少4周的患者可评估分析。

主要发现

  • 2019年7月至2020年11月共入组55例患者,数据截止2021年9月时50例可评估患者中4例仍在治疗。
  • 17例(34%)患者在6个月时无进展。
  • 客观缓解率为16%(95% CI,8.3至28.5),包括1例完全缓解和7例部分缓解。
  • 中位随访17.6个月,中位无进展生存期为3.4个月(95% CI,2.8至6.2),中位总生存期为8.0个月(95% CI,7.5至14.3)。
  • 8例(16%)发生3级治疗相关不良事件,主要为贫血;无4级或5级治疗相关不良事件。

关键数值与推荐

  • 主要终点为6个月无进展生存率,疗效定义为≥50%的患者在6个月时无进展。
  • 次要终点包括安全性、客观缓解和总生存期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with advanced endometrial cancer have a poor prognosis, and treatment options are limited. The investigator-initiated, multicenter, phase II DOMEC trial (NCT03951415) is the first trial to report data on efficacy and safety of combined treatment with PD-L1 and PARP inhibition for advanced endometrial cancer. PATIENTS AND METHODS: Patients with metastatic or recurrent endometrial cancer were enrolled. Patients received durvalumab 1500 mg intravenously q4w and olaparib 300 mg 2dd until disease progression, unacceptable toxicity, or patient withdrawal. Patients with at least 4 weeks of treatment were evaluable for analysis. The primary endpoint was progression-free survival at 6 months. Evidence for efficacy was defined as progression-free survival at 6 months in ≥50% of patients. Secondary endpoints included safety, objective response and overall survival. RESULTS: From July 2019, through November 2020, 55 patients were enrolled. At data cut-off (September 2021), 4 of the 50 evaluable patients were still on treatment. Seventeen patients (34%) were progression-free at 6 months. Objective response rate was 16% (95% CI, 8.3 to 28.5) with 1 complete and 7 partial responses. With a median follow-up of 17.6 months, median progression-free survival was 3.4 months (95% CI, 2.8 to 6.2) and median overall survival was 8.0 months (95% CI, 7.5 to 14.3). Grade 3 treatment-related adverse events occurred in 8 patients (16%), predominantly anemia. There were no grade 4 or 5 treatment-related adverse events. CONCLUSION: The combination of durvalumab and olaparib was well tolerated, but did not meet the prespecified 50% 6-month progression-free survival in this heterogeneous patient population with advanced endometrial cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Post CCB, Westermann AM, Boere IA, et al. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial). Gynecol Oncol. 2022. PMID: 35287967. doi:10.1016/j.ygyno.2022.02.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。